Position in TCRX
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$30,098
+$5,698 QoQ
Shares Held
29,800
+22.1% QoQ
Ownership
0.046%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2022
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TCRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026PRUDENTIAL FINANCIAL INC holds $507,740,529 across 170 Biotechnology names. TCRX ranks #161 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
140,491 | $108,548,965 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
131,560 | $58,746,801 | |
| 3 | INCY |
Incyte Corp
|
374,280 | $35,227,233 | |
| 4 | EXEL |
Exelixis, Inc.
|
463,825 | $19,893,454 | |
| 5 | LGND |
Ligand Pharmaceuticals Inc
|
64,133 | $12,804,153 | |
| 6 | ALMS |
Alumis Inc.
|
538,733 | $11,868,287 | |
| 7 | PTCT |
Ptc Therapeutics, Inc.
|
164,570 | $11,212,154 | |
| 8 | PTGX |
Protagonist Therapeutics, Inc
|
95,235 | $10,037,769 |
All Filings in TCRX
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $30,098 | 29,800 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $24,400 | 24,400 | Shares | Defined | 2026-02-13 | |
| 2025-09-30 | $20,930 | 11,500 | Shares | Defined | 2025-11-13 | |
| 2025-03-31 | $15,173 | 10,995 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $31,661 | 10,415 | Shares | Defined | 2025-02-11 | |
| 2022-12-31 | $19,840 | 12,800 | Shares | Defined | 2023-02-14 | |
| 2022-09-30 | $33,550 | 11,000 | Shares | Defined | 2022-11-04 | |
| No filing history on record for this holder in this stock. | ||||||